Dovato is manufactured by ViiV Healthcare [1][2]. ViiV Healthcare is a global specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer, with Shionogi also as a strategic partner [1].
How does Dovato work?
Dovato is a combination antiretroviral medication used to treat HIV-1 infection [3]. It contains two active ingredients: dolutegravir and lamivudine [3]. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV from multiplying by blocking the integrase enzyme [4]. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that works by stopping the virus from growing [4].
What is Dovato used for in HIV treatment?
Dovato is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 30 kg who have no known or suspected past or present viral resistance to either dolutegravir or lamivudine [3]. It offers a complete regimen in a single tablet taken once daily [3].
What are the alternatives to Dovato for HIV treatment?
There are various treatment options for HIV, including other single-tablet regimens (STRs) that combine multiple antiretroviral drugs. Examples include Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) and Triumeq (abacavir/dolutegravir/lamivudine) [5][6]. The choice of treatment depends on individual patient factors, including resistance profiles, comorbidities, and potential drug interactions [5].
When does the patent for Dovato expire?
The patent landscape for HIV medications can be complex, with multiple patents covering different aspects of a drug, including composition, manufacturing, and use [7]. Information on specific patent expiry dates for Dovato, including dolutegravir and lamivudine components, can be found through resources like DrugPatentWatch.com [7]. These dates are crucial for understanding when generic versions may become available.
What clinical trials support Dovato's use?
Dovato's efficacy and safety are supported by clinical trials, such as the pivotal Phase III 2-drug regimen studies (e.g., GEMINI 1 & 2) which demonstrated that maintaining virologic suppression with dolutegravir and lamivudine was non-inferior to continuing a three-drug regimen in virologically suppressed adults with HIV-1 [3][8].
What are the common side effects of Dovato?
Common side effects reported with Dovato include insomnia, headache, and nausea [3]. More serious side effects, although less common, can occur and may include hypersensitivity reactions, liver problems, and psychiatric effects [3]. Patients should discuss any concerns with their healthcare provider [3].
Who manufactures the components of Dovato?
Dolutegravir is a key component of Dovato, and it was developed by ViiV Healthcare [1][4]. Lamivudine is another component, also incorporated into Dovato by ViiV Healthcare [1][4].
What is the price of Dovato?
The cost of Dovato can vary depending on insurance coverage, pharmacy, and geographic location. It is a prescription medication, and patients should consult with their healthcare provider and insurance provider for specific pricing information [9].
Sources:
[1] https://www.viivhealthcare.com/en-us/our-business/hiv-medicines/dovato/
[2] https://www.viivhealthcare.com/en-us/
[3] https://www.dovato.com/
[4] https://www.drugpatentwatch.com/p/dovato-dolutegravir-lamivudine
[5] https://www.hiv.va.gov/patient/drug/index.html
[6] https://www.gilead.com/treatment- R/hiv/biktarvy
[7] https://www.drugpatentwatch.com/
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609468/
[9] https://www.dovato.com/support-and-resources/financial-assistance